Dean Lloyd H 4

What Happened

• Dean Lloyd, a director of Progyny, was granted a total of 34,995 equity awards on May 21, 2026. The filing shows two awards: 6,792 shares acquired (award) and 28,203 shares reported as a derivative award. Both grants were recorded at $0.00 (no cash paid) for a total reported value of $0.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26 (filed after the transaction date).
• Award amounts and prices: 6,792 shares (A) at $0.00; 28,203 derivative shares (A) at $0.00. Total awarded = 34,995 shares; reported cash value = $0.
• Vesting/further terms: Footnote F1 states the RSUs represent a contingent right to one share each; they vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately before the issuer’s first annual meeting after the grant, subject to continued service. Footnote F2 gives the same vesting schedule for the derivative award.
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filing was submitted five days after the transaction date; this is later than the typical two-business-day Form 4 reporting window.

Context

• These were awards (grant of restricted/derivative units), not open-market purchases or sales. RSU/derivative awards are typically contingent on continued service and vesting conditions; they do not represent immediate cash proceeds or a sale.